Leveraging ground-breaking technology to bring game-changing therapies to patients living with cancer

ABOUT US

ABOUT US

Our mission is to leverage world-class technologies, our oncology expertise and extensive R&D and commercial experience to approach innovation in cancer therapeutics in a way that combines the pragmatic with the visionary.

Our home is in Zug, Switzerland, our minds are on the art of oncology drug development, and our hearts are with patients living with cancer.

We are Laevoroc Oncology.

Watch our story

PIPELINE

Our pipeline is housed within three independent subsidiaries.

Developing different assets within contained subsidiaries means they can proceed independently, and, we can make independent financing and licensing/sales agreements. We see this as an important way to make the company more resilient, and better align with the interests of potential partners, and ultimately patients.

space

Laevoroc Chemotherapy

is progressing LR 06 (a patented oral gemcitabine prodrug for maintenance therapy in pancreatic, ovarian and breast cancers). With LR 06 we are reimagining the use of one of the most important chemotherapy agents worldwide, gemcitabine, by developing a unique, patented, oral prodrug form to create differentiated uses. The innovation of rationally designing a new molecule for oral administration is about providing a cancer therapy that provides a low healthcare system burden, and a low patient burden.

microscope

Laevoroc Immunology

is progressing LR 09 (a highly potent and selective PNP inhibitor). With LR 09 we are developing a novel molecule to guide the immune system by receptor activation to eradicate relapsed leukemia after allogeneic stem cell transplantation. Our vision is to enable the cure of this disease, which is catastrophic medically after relapse. Relapse post transplantation is the most frequent cause of treatment failure, in children and adults. Our innovation is a game-changing new therapy with the potential to become standard of care.

shutterstock_661092253 (5)

Laevoroc Neuro-Oncology

is the core of our company and will build a pipeline of innovative drugs addressing brain cancers. Right now, we are progressing LR 02 (a highly selective and potent ATR inhibitor with outstanding CNS penetration). With LR 02 we are introducing a highly innovative therapeutic principle to beating brain cancer with a new mode of action based on synthetic lethality. Brain tumors are among the most difficult to treat and most feared forms of cancer, and it is a disease with a dismal survival rate: the average is just 15 months.

PIPELINE

Our pipeline is housed within three independent subsidiaries.

Developing different assets within contained subsidiaries means they can proceed independently, and, we can make independent financing and licensing/sales agreements. We see this as an important way to make the company more resilient, and better align with the interests of potential partners, and ultimately patients.

space

Laevoroc Chemotherapy

is progressing LR 06 (a patented oral gemcitabine prodrug for maintenance therapy in pancreatic, ovarian and breast cancers). With LR 06 we are reimagining the use of one of the most important chemotherapy agents worldwide, gemcitabine, by developing a unique, patented, oral prodrug form to create differentiated uses. The innovation of rationally designing a new molecule for oral administration is about providing a cancer therapy that provides a low healthcare system burden, and a low patient burden.

space

Laevoroc Chemotherapy

is progressing LR 06 (a patented oral gemcitabine prodrug for maintenance therapy in pancreatic, ovarian and breast cancers). With LR06 we are reimagining the use of one of the most important chemotherapy agents worldwide, gemcitabine, by developing a unique, patented, oral prodrug form to create differentiated uses. The innovation of rationally designing a new molecule for oral administration is about providing a cancer therapy that provides a low healthcare system burden, and a low patient burden.

microscope

Laevoroc Immunology

is progressing LR 09 (a highly potent and selective PNP inhibitor). With LR 09 we are developing a novel molecule to guide the immune system by receptor activation to eradicate relapsed leukemia after allogeneic stem cell transplantation. Our vision is to enable the cure of this disease, which is catastrophic medically after relapse. Relapse post transplantation is the most frequent cause of treatment failure, in children and adults. Our innovation is a game-changing new therapy with the potential to become standard of care.

Microscopic image

Laevoroc Immunology


is progressing LR09 (a highly potent and selective PNP inhibitor). With LR09 we are developing a novel molecule to guide the immune system by receptor activation to eradicate relapsed leukemia after allogeneic stem cell transplantation. Our vision is to enable the cure of this disease, which is catastrophic medically after relapse. Relapse post transplantation is the most frequent cause of treatment failure, in children and adults, and our innovation is a game-changing new form of therapy with the potential to become standard of care.

brain

Laevoroc Neuro-Oncology

is the core of our company and will build a pipeline of innovative drugs addressing brain cancers. Right now, we are progressing LR 02 (a highly selective and potent ATR inhibitor with outstanding CNS penetration). With LR 02 we are introducing a highly innovative therapeutic principle to beating brain cancer with a new mode of action based on synthetic lethality. Brain tumors are among the most difficult to treat and most feared forms of cancer, and it is a disease with a dismal survival rate: the average is just 15 months.

shutterstock_1809283648

Laevoroc Neuro-Oncology

is the core of our company and will build a pipeline of innovative drugs addressing brain cancers. Right now, we are progressing LR 02 (a highly selective and potent ATR inhibitor with outstanding CNS penetration). With LR02 we are introducing a highly innovative therapeutic principle to beating brain cancer with a new mode of action based on synthetic lethality. Brain tumors are among the most difficult to treat and most feared forms of cancer, and it is a disease with a dismal survival rate: the average is just 15 months.

space
Laevoroc Chemotherapy

is progressing LR 06 (a patented oral gemcitabine prodrug for maintenance therapy in pancreatic, ovarian and breast cancers). With LR 06 we are reimagining the use of one of the most important chemotherapy agents worldwide, gemcitabine, by developing a unique, patented, oral prodrug form to create differentiated uses. The innovation of rationally designing a new molecule for oral administration is about providing a cancer therapy that provides a low healthcare system burden, and a low patient burden.

microscope
Laevoroc Immunology

is progressing LR 09 (a highly potent and selective PNP inhibitor). With LR 09 we are developing a novel molecule to guide the immune system by receptor activation to eradicate relapsed leukemia after allogeneic stem cell transplantation. Our vision is to enable the cure of this disease, which is catastrophic medically after relapse. Relapse post transplantation is the most frequent cause of treatment failure, in children and adults. Our innovation is a game-changing new therapy with the potential to become standard of care.

Laevoroc Neuro-Oncology

is the core of our company and will build a pipeline of innovative drugs addressing brain cancers. Right now, we are progressing LR 02 (a highly selective and potent ATR inhibitor with outstanding CNS penetration). With LR 02 we are introducing a highly innovative therapeutic principle to beating brain cancer with a new mode of action based on synthetic lethality. Brain tumors are among the most difficult to treat and most feared forms of cancer, and it is a disease with a dismal survival rate: the average is just 15 months.

Our company was founded in 2019, initially as TNT Medical, by Thomas Mehrling MD PhD, and Davide Guggi PhD, who have over 40 years combined experience in oncology and the pharma industry.
Our company was founded in 2019, initially as TNT Medical, by Thomas Mehrling MD PhD, and Davide Guggi PhD, who have over 40 years combined experience in oncology and the pharma industry.
Davide Guggi, PhD                                                      CSO and Co-Founder

Entrepreneur and former head of business unit at Mundipharma AT; CMC expert and QP with over 15 years’ experience in oncology drug development.
Thomas Mehrling, MD, PhD      CEO and Founder

Entrepreneur and former CEO of Mundipharma EDO, with over 20 years’ experience in oncology drug development.

Thomas Mehrling, MD, PhD
CEO and Founder

Entrepreneur and former CEO of Mundipharma EDO, with over 20 years’ experience in oncology drug development

Davide Guggi, PhD
CSO and Co-Founder


Entrepreneur and former head of business unit at Mundipharma AT; CMC expert and a QP, with over 15 years’ experience in oncology drug development.
Thomas Mehrling, MD, PhD
CEO and Founder
Entrepreneur and former CEO of Mundipharma EDO, with over 20 years’ experience in oncology drug development.
Davide Guggi, PhD
CSO and Co-Founder
Entrepreneur and former head of business unit at Mundipharma AT; CMC expert and QP with over 15 years’ experience in oncology drug development.

Other Key Team Members Include:

     Shanta Bantia,  PhD

CSO, Laevoroc Immunology

Entrepreneur, founder and CEO of Nitor Therapeutics, with over 20 years’ experience in the pharmaceutical industry.

Steve Engen, MBA

 

Business Development
Strategic Advisor

Entrepreneur with over 20 years’ experience in the biopharma industry and business development, with a focus on East Asia.

Jessica Kourniakti, DPhil

COO, Laevoroc Oncology

Entrepreneur, owner and CEO of Manage Mind AG, with over 6 years’ experience leading operations and communications projects.

Shanta Bantia, PhD – CSO, Laevoroc Immunology

Entrepreneur, founder and CEO of Nitor Therapeutics, with over 20 years’ experience in the pharmaceutical industry.

Steve Engen, MBA – Business Development Strategic Advisor

 

Entrepreneur with over 20 years’ experience in the biopharma industry and business development, with a focus on East Asia.

Jessica Kourniakti, DPhil – COO, Laevoroc Oncology

Entrepreneur, owner and CEO of Manage Mind AG, with over 6 years’ experience leading operations and communications projects.

PARTNERS

Academic Partners

Commercial Partners

Outsourced Partners

NEWS & EVENTS

Highlights

banner 1 (1)

07/07/2021 — Laevoroc Oncology Unveils Immunology Subsidiary with CSO Shanta Bantia to Develop PNP Inhibitor for Eradication of Relapsed Leukemia

Laevoroc Oncology Unveils Immunology Subsidiary with CSO Shanta Bantia to Develop PNP Inhibitor for Eradication of Relapsed Leukemia Laevoroc Immunology formed to focus on development of a highly potent Purine...

News and events

swiss biotech

Swiss Biotech Day

Laevoroc Oncology will be attending Swiss Biotech Day, which is scheduled to take place on September 7, 2021.

Highlights

banner 1 (1)

07/07/2021 — Laevoroc Oncology Unveils Immunology Subsidiary with CSO Shanta Bantia to Develop PNP Inhibitor for Eradication of Relapsed Leukemia

Laevoroc Oncology Unveils Immunology Subsidiary with CSO Shanta Bantia to Develop PNP Inhibitor for Eradication of Relapsed Leukemia Laevoroc Immunology formed to focus on development of a highly potent Purine...

News and events

Swiss Biotech Day

Laevoroc Oncology will be attending Swiss Biotech Day, which is scheduled to take place on September 7, 2021.

Highlights

News and events

Swiss Biotech Day

Laevoroc Oncology will be attending Swiss Biotech Day, which is scheduled to take place on September 7, 2021.